0001493152-23-009202.txt : 20230328 0001493152-23-009202.hdr.sgml : 20230328 20230328080540 ACCESSION NUMBER: 0001493152-23-009202 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230328 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230328 DATE AS OF CHANGE: 20230328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProPhase Labs, Inc. CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 23766253 BUSINESS ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 BUSINESS PHONE: (215) 345-0919 MAIL ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 FORMER COMPANY: FORMER CONFORMED NAME: QUIGLEY CORP DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm
0000868278 false 0000868278 2023-03-28 2023-03-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 28, 2023

 

PROPHASE LABS, INC.

(Exact name of Company as specified in its charter)

 

Delaware   000-21617   23-2577138

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

711 Stewart Avenue, Suite 200

Garden City, New York

   11530
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (215) 345-0919

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, par value $0.0005   PRPH   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On March 28, 2023, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 7.01 Regulation FD.

 

As previously announced, the Company will conduct a conference call today, Tuesday, March 28, 2023, at 11:00 a.m. (Eastern Time) to discuss its financial results and provide an update on corporate developments.

 

The information included in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

No.   Description
     
99.1   Press Release dated March 28, 2023
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ProPhase Labs, Inc.
     
  By: /s/ Robert Morse Jr.
    Robert Morse Jr.
    Controller (principal financing officer and principal accounting officer)

 

Date: March 28, 2023

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

ProPhase Labs Announces Record Financial Results

for the year ended December 31, 2022

 

Company highlights key strategic initiatives to grow underlying value in 2023 and beyond

 

Company announces it is in strategic discussions to develop BE-Smart cancer test globally

 

Company to hold a conference call Tuesday, March 28, 2023, at 11:00AM ET

 

Garden City, NY – March 28, 2023 (GLOBE NEWSWIRE) – ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today reported its financial and operational results for the year ended December 31, 2022.

 

Financial highlights for the full year ended December 31, 2022, include the following:

 

  ● Net revenue of $122.6 million for the year ended December 31, 2022, as compared to $79.0 million for the year ended December 31, 2021, an increase of approximately 55%.
     
  ● Net Income of $18.5 million, or $1.17 per diluted share, for the year ended December 31, 2022, as compared to net income of $6.3 million, or $0.41 per share, for the year ended December 31, 2021.
     
  ● Adjusted EBITDA of $38.6 million for the year ended December 31, 2022, as compared to adjusted EBITDA of $18.1 million for the year ended December 31, 2021.
     
  ● Cash, cash equivalents and marketable equity securities of $17.4 million and working capital of $44.6 million as of December 31, 2022.

 

Corporate highlights for the year ended December 31, 2022, and subsequently include the following:

 

  ● Acquired exclusive worldwide rights to develop and commercialize, subject to the necessary regulatory approvals, Equivir (dietary supplement) and Equivir G (Rx), two broad-based anti-virals.
     
  ● Acquired exclusive worldwide rights to develop and commercialize Linebacker (LB-1 and LB-2) for the treatment of cancer, inflammatory diseases or symptoms and memory-related syndromes, diseases or symptoms, including dementia and Alzheimer’s disease.
     
  ● Built out Nebula Genomics infrastructure, hired key management, added Dr. Russ Altman of Stanford University to our advisory board, and set the company on an accelerated growth path going forward.
     
  ● Returned a total of 1.3 million shares to the Company in 2022 from our common stock repurchase plan and cashless stock options exercised at a total value of $11.3 million.
     
  ● Paid two stock dividends to stockholders in 2022 totaling $9.3 million.
     
  ● Subsequent to year-end 2022, acquired exclusive worldwide rights to the BE-Smart Esophageal Pre-Cancer diagnostic screening test and related intellectual property assets.
     
  ● Subsequent to year-end 2022, received Board of Directors approval for a new $6 million stock repurchase program.

 

Ted Karkus, ProPhase Lab’s Chief Executive Officer, commented, “While working on Wall Street in the 90’s, I learned that when it comes to investing, particularly in small cap development stage companies, bet on the jockey and not the horse. My fellow shareholders, you have all bet on the right jockey. Our results over the past decade and in particular over the last few years, which have proven to be a very difficult period for many companies, have been extraordinary for our company, and 2022 was no exception. I am so proud of our entire management team for what we have collectively accomplished, and the platform that we have built together to provide an exciting future for our company and our shareholders.”

 

   
 

 

Mr. Karkus continued, “A decade ago, we inherited a cold brand with declining sales. Management had the skill and foresight to turn it around and sell it for $50 million dollars. Unlike the managements of many other companies, we rewarded shareholders with stock buybacks and special dividends and did not squander a single penny. We then looked for opportunities and were patient, only swinging at balls that we felt could result in homeruns for our company. With the emergence of COVID-19, we found an opportunity to help people while generating immediate and significant returns. The financial results speak for themselves.”

 

“I am truly pleased with our full year 2022 revenues of $122.6 million and adjusted EBITDA of $38.6 million,” continued Mr. Karkus. “One item to clarify is a one-time year-end charge of $5.9 million related to bad debt write-offs. This charge relates to the first half of 2022 when HRSA stopped reimbursing COVID-19 testing providers for claims without insurance. While this write-off is prudent, we still hope to collect insurance on many of these claims.”

 

“I believe that it is our destiny to build a multi-billion-dollar company together,” continued Mr. Karkus. “While our financial results have been stellar, we believe that our diversification strategy, which began in 2022, will make our previous successes seem trivial in comparison to what is yet to come. Over the past two years, we have taken advantage of the bear market in micro-cap development stage biotech and life sciences companies and licensed and/or acquired some fantastic assets that will gestate and become potentially billion-dollar franchises on their own.”

 

“As our COVID-19 and flu testing slows in 2023, we believe that the underlying value of our other subsidiaries will continue to grow rapidly and will more than make up for the slowdown in our diagnostics business and will reward our shareholders significantly over time. Several of these subsidiaries are already beginning to operate exceptionally well.”

 

Mr. Karkus elaborated, “Revenues from our Pharmaloz Manufacturing subsidiary are up approximately 100% year-over-year and we expect them to triple over the next two years. We already have the demand and are only limited by how quickly we can build out our capacity. Our Nebula Genomics subsidiary is growing even faster. We estimate revenues for this business will grow more than 100% in 2023 and that is before we leverage off of our superior retail distribution network. If we are successful in gaining acceptance in major retailers, then sales will grow even more dramatically. Retail is something we know better than anyone and we expect to execute on this in the near term.”

 

“We are confident that combining Nebula Genomics’ comprehensive genomic testing with our CLIA-certified lab capabilities will lead to faster turnaround times and lower price points, driving additional demand,” Mr. Karkus continued. “We also plan to offer low-pass genomic testing at significantly lower price points. This will allow us to leverage our distribution network of more than 40,000 food, drug, and mass retail stores to further expand direct-to-consumer and big-box retail distribution of Nebula’s Genomic sequencing products and services. Additional goals include the development of partnerships for Nebula Genomic’s proprietary library, research collaborations with universities, and leveraging the Nebula Genomics database. Furthermore, we believe our lab will be one of the most sophisticated in the nation and therefore could become the go to spot for all genetic sample processing. Each of these initiatives could significantly grow sales as we look forward to 2023 and beyond.”

 

Mr. Karkus continued, “We are very excited to be developing the BE-Smart Esophageal Cancer Test. Testing is ongoing at mProbe in collaboration with Dr. Hartley and The Mayo Clinic as well as with several other Key Opinion Leaders around the country. As described in recent press releases, we believe the BE-Smart test has multi-billion-dollar potential with minimal competition and significant unmet need. We expect to pursue initial commercialization of the BE-Smart test later this year as a laboratory developed test (LDT) and for research use only (RUO) for cash payment. Full commercialization backed by insurance is expected to commence in the first half of 2024 once CPT codes are obtained for insurance reimbursement. In parallel, we are also in current discussions to explore strategic opportunities to potentially develop, commercialize and distribute our BE-Smart test globally. These global opportunities may be even larger than in the United States. In the longer-term we feel that our knowledge gained from the BE-Smart test could also lead to some significant opportunities for therapeutic applications for Esophageal Adeno Carcinoma (EAC).”

 

   
 

 

“As shareholders, we look for catalysts to drive performance,” added Mr. Karkus. “We believe our ProPhase BioPharma subsidiary has exciting potential in both the short-term and the long-term. We are currently conducting clinical studies of Equivir (OTC/dietary supplement), a broad based anti-viral, and anticipate launching Equivir (OTC/dietary supplement) in the United States in the second half of this year. We believe that this product has significant potential as a dietary supplement and leverages our core infrastructure from when we owned the Cold-EEZE Cold Remedy brand. Our Linebacker cancer compound (LB-1) continues to demonstrate excellent pre-clinical results as a potential cancer co-therapy for several billion-dollar cancer drugs. These studies are continuing at Dana Farber Cancer Institute, and we look forward to reporting additional progress in the second quarter of this year. Longer term, we do not plan to spend significantly on this development path and plan to sell, license or joint venture Linebacker once Phase 1 human clinical studies are completed at minimal cost to ProPhase shareholders.”

 

“And finally, our diversification strategy for our diagnostics laboratory is proceeding nicely. Our clinical lab and our genomics lab have both been fully constructed with equipment installed. We are in the final stages of completing clinical validations to ensure testing accuracy for regulatory obligations. Our genomics laboratory is equipped with state-of-the-art genomics equipment, which provides us with the opportunity to potentially be the low-cost provider of all whole genome sequencing in the United States, as well as a leading provider of other genomics tests. We will also continue to evaluate and pursue additional strategic and synergistic acquisitions to build our precision medicine and genomics research capabilities with the help of world-renowned genomics expert, George Church, co-founder of Nebula Genomics and Russ Altman, both of whom are advisors to ProPhase Labs.”

 

Mr. Karkus concluded, “As the largest shareholder in the Company, my primary concern has always been on creating value and a return on investment, on both an absolute and per share basis. While long-term performance is really just a series of good short-term executions, I remain focused on both the near-term and the long-term. In 2022, we returned a total of 1.3 million shares to the Company from the combination of our common stock repurchase plan and cashless stock options exercised at a total value of $11.3 million. Our recently announced new $6 million dollar stock repurchase program is a testament to our significant execution over the past two years as well as the Board’s confidence in our multi-faceted strategy to continue to build value for our shareholders long-term. Suffice it to say, the Board of Directors and I are excited for the future of our Company.”

 

Financial Results

 

Year Ended December 31, 2022

 

Net revenue for the year ended December 31, 2022 increased $43.6 million, or 55%, to $122.6 million compared to $79.0 million for the year ended December 31, 2021. The increase in net revenue was the result of a $39.8 million increase from diagnostic services, and a $3.8 million increase from consumer products. The increase in net revenue from diagnostic services was due to increased COVID-19 testing volumes performed as a result of the spread of the Omicron variant, which emerged in early 2022. Overall diagnostic testing volume increased from approximately 600,000 tests for the year ended December 31, 2021 to approximately 1,000,000 tests for the year ended December 31, 2022, of which 58% and 29% were reimbursed by the HRSA uninsured program, respectively. The average variable consideration received was $108.00 per adjudicated test for the year ended December 31, 2022 compared to $114.00 per adjudicated test for the year ended December 31, 2021 .

 

Cost of revenues for the year ended December 31, 2022 was $52.0 million, comprised of $39.9 million for diagnostic services and $12.1 million for consumer products. Cost of revenues for the year ended December 31, 2021 were $37.1 million comprised of $29.4 million for diagnostic services and $7.6 million for consumer products.

 

We realized a gross profit of $70.7 million for the year ended December 31, 2022, as compared to $42.0 million for the year ended December 31, 2021. The increase for the year ended December 31, 2022 compared to the year ended December 31, 2021 of $28.7 million attributable to an increase in diagnostic services, while consumer products remained flat. For the year ended December 31, 2022, our overall gross margin was 57.6% as compared to 53.1% for the year ended December 31, 2021. Gross margin for diagnostic services was 63.2% and 57.1% for the years ended December 31, 2022 and 2021, respectively. The increase in gross margin was principally due (i) increased efficiencies in our lab processing, (ii) decreased sample collection costs and (iii) a decrease in cost of testing materials. Gross margin for consumer products was 15.5% and 27.1% for the years ended December 31, 2022 and 2021, respectively. Gross margin for consumer products has historically been influenced by fluctuations in quarter-to-quarter production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to market write-downs and timing of shipments to customers.

 

   
 

 

Diagnostic expenses for the year ended December 31, 2022 were $12.0 million as compared to $9.2 million of diagnostic expenses for the year ended December 31, 2021. The increase in diagnostic expenses of $2.8 million was primarily due to increased COVID-19 testing volumes performed as a result of the spread of the Omicron variant, which emerged in early 2022, partially offset by a greater proportion of costs allocated to cost of revenues as a result of the nature of agreements with network providers.

 

General and administration expenses increased $11.9 million for the year ended December 31, 2022 to $34.4 million as compared to $22.5 million for the year ended December 31, 2021. The increase in general and administration expenses for the year ended December 31, 2022 as compared to the year ended December 31, 2021 was primarily related to an increase in personnel expenses and professional fees associated with our diagnostic services business. Additionally, we recorded a bad debt expense of $5.9 million representing a direct write-off of trade receivables we have determined to be uncollectible.

 

Research and development costs for the year ended December 31, 2022 were $0.7 million as compared to $0.5 million for the year ended December 31, 2021. The increase in research and development costs in fiscal 2022 as compared to fiscal 2021 was principally due to a decrease in personnel expenses associated with our diagnostics services business.

 

Our aggregate cash and cash equivalents and restricted cash as of December 31, 2022 were $9.1 million as compared to $8.7 million at December 31, 2021. Our working capital was $44.8 million and $45.8 million as of December 31, 2022 and 2021, respectively. The increase of $0.5 million in our cash and cash equivalents for the year ended December 31, 2022 was primarily due to the proceeds from the sale and maturities of marketable debt securities of $8.2 million, proceeds from dispositions of property and other assets of $0.5 million, and $28.7 million in cash provided by operating activities, offset by (i) purchases of marketable securities of $6.8 million, (ii) cash dividend payments of $9.3 million, (iii) repayment of note payable of $7.0 million, (iv) repurchase of common shares for $2.2 million, and (v) capital expenditures of $4.1 million.

 

Conference Call and Webcast Details

 

Management will host a conference call at 11:00 AM ET, March 28, 2023, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.

 

Participants can register for the conference call by navigating to: https://dpregister.com/sreg/10176786/f8a78067aa

 

Please note that registered participants will receive their dial in number upon registration and may dial directly into the call without delay. Those without internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (domestic), or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into ProPhase Lab’s call.

 

The conference call will be broadcast live and available for replay at https://event.choruscall.com/mediaframe/webcast.html?webcastid=Fg5WDKxb and via the investor relations section of the Company’s website at www.ProPhaseLabs.com.

 

A webcast replay of the call will be available approximately two hours after the end of the call at the above links. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code #7800122.

 

   
 

 

About ProPhase Labs

 

ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”) is a growth oriented and diversified diagnostics, genomics and biotech company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics database to be used for further research. The Company provides traditional CLIA molecular laboratory services, including COVID-19 testing. The Company also operates Pharmaloz, a rapidly growing contract manufacturing subsidiary, and offers the TK Supplements line of dietary supplements, which are distributed in food, drug, and mass stores throughout the country.

 

ProPhase Diagnostics, Inc., a wholly owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19) and Influenza A and Influenza B. Critical to COVID-19 testing, ProPhase Diagnostics provides fast turnaround times for results. ProPhase Diagnostics also offers best-in-class rapid antigen tests to broaden its COVID-19 testing beyond RT-PCR testing. The Company has announced plans for the expansion of the lab to include traditional clinical testing and genomics sequencing.

 

Nebula Genomics, a rapidly growing and wholly owned subsidiary of ProPhase, focuses on genomics sequencing and testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic sequencing may help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression. The Company currently offers Nebula Genomics whole genome sequencing products direct-to-consumer online, with plans to sell in food, drug and mass (FDM) stores and to provide testing for universities conducting genomic research.

 

ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds. Licensed compounds currently include Equivir (OTC/dietary supplement) and Equivir G (Rx), two broad based anti-virals, and Linebacker LB-1 and LB-2, two small molecule PIM kinase inhibitors. The Company is collaborating with the Dana Farber Cancer Institute to develop LB-1 as a cancer co- therapy. The Company also owns the exclusive rights to the BE-Smart Esophageal Pre-Cancer Diagnostic Screening test and related IP assets. The BE-Smart test remains under validation as a LDT. The test is focused on the early detection of esophageal cancer and is intended to provide health care providers and patients with data to help determine treatment options.

 

ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements under the TK Supplements® brand and Pharmaloz contract manufacturing subsidiary. ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products.

 

Forward Looking Statements

 

Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our plans to grow our subsidiaries and build a multi-billion dollar company, our expectations regarding the future revenue growth potential of each of our subsidiaries, our ability to collect insurance from HRSA for COVID-19 testing in the future, the ability of Nebula Genomics to offer faster turnaround times and lower prices for our whole-genome sequencing products and our plans to sell these products in food, drug and mass (FDM) stores and to develop partnerships for Nebula Genomics’ proprietary library, develop research collaborations with universities and leverage its database, our expected timeline for commercializing our BE-Smart Test and its market potential, our expected timeline for launching Equivir (OTC/dietary supplement) and its market potential, our anticipated timing for reporting additional preclinical results for our Linebacker (LB-1) compound and our development plans for LB-1, as well as our plans to expand our New York lab to include traditional clinical testing and genomic sequencing. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.

 

For more information, visit www.ProPhaseLabs.com.

 

ProPhase Media Relations and Institutional Investor Contact:

 

ProPhase Labs, Inc.
267-880-1111
investorrelations@prophaselabs.com

 

ProPhase Retail Investor Relations Contact:

 

Renmark Financial Communications
John Boidman
514-939-3989
Jboidman@renmarkfinancial.com

 

Source: ProPhase Labs, Inc.

 

   
 

 

PROPHASE LABS, INC

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(in thousands)

 

   DECEMBER 31, 2022   DECEMBER 31, 2021 
ASSETS          
Current assets          
Cash and cash equivalents  $9,109   $8,408 
Restricted cash   —    250 
Marketable debt securities, available for sale   8,328    8,779 
Marketable equity securities, at fair value   —    76 
Accounts receivable, net   37,054    37,708 
Inventory, net   3,976    4,600 
Prepaid expenses and other current assets   2,366    1,496 
Total current assets   60,833    61,317 
           
Property, plant and equipment, net   7,288    5,947 
Secured promissory note receivable   —    — 
Prepaid expenses, net of current portion   121    460 
Right-of-use asset, net   4,059    4,402 
Intangible assets, net   8,475    10,852 
Goodwill   5,709    5,709 
Other assets   1,163    608 
TOTAL ASSETS  $87,648   $89,295 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable  $5,905   $7,026 
Accrued diagnostic services   1,009    1,890 
Accrued advertising and other allowances   99    104 
Lease liabilities   301    663 
Deferred revenue   2,499    2,034 
Income tax payable   4,190    1,312 
Other current liabilities   2,072    2,495 
Total current liabilities   16,075    15,524 
           
Non-current liabilities:          
Deferred revenue, net of current portion   1,059    905 
Deferred tax liability   224    — 
Note payable   —    44 
Unsecured convertible promissory notes, net   2,400    9,996 
Lease liabilities, net of current portion   4,259    4,198 
Total non-current liabilities   7,942    15,143 
Total liabilities   24,017    30,667 
           
COMMITMENTS AND CONTINGENCIES          
           
Stockholders’ equity          
Preferred stock authorized 1,000,000, $0.0005par value, no shares issued and outstanding   —    — 
Common stock authorized 50,000,000, $0.0005par value, 15,485,900and 11,604,253shares outstanding, respectively   16    16 
Additional paid-in capital   109,138    104,552 
Retained earnings (accumulated deficit)   11,753    2,642 
Treasury stock, at cost, 16,818,846and 16,652,022shares, respectively   (58,033)   (48,407)
Accumulated other comprehensive loss   757    (175)
Total stockholders’ equity   63,631    58,628 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $87,648   $89,295 

 

   
 

 

PROPHASE LABS, INC

CONSOLIDATED STATEMENT OF OPERATIONS

(UNAUDITED)

(in thousands) 

  

   For the years ended 
   DECEMBER 31, 2022   DECEMBER 31, 2021 
Revenues, net  $122,647   $79,042 
Cost of revenues   51,993    37,054 
Gross profit   70,654    41,988 
           
Operating expenses:          
Diagnostic expenses   12,022    9,174 
General and administration   34,385    22,493 
Research and development   652    520 
Total operating expenses   47,059    32,187 
Gain on sale of real estate   —    — 
Income (loss) from operations   23,595    9,801 
           
Interest income, net   153    642 
Interest expense   (764)   (1,148)
Change in fair value of investment securities   (76)   (240)
Impairment of secured promissory note receivable   —    (3,750)
Income from operations before income taxes   22,908    5,305 
Income tax benefit (expense)   (4,445)   968 
Income from operations after income taxes   18,463    6,273 
Net income  $18,463   $6,273 
           
Other comprehensive income (loss):          
Unrealized income (loss) on marketable debt securities   932    (164)
Total comprehensive income  $19,395   $6,109 
           
Earnings per share:          
Basic  $1.17   $0.41 
           
Diluted  $1.02   $0.40 
           
Weighted average common shares outstanding:          
Basic   15,845    15,172 
Diluted   18,651    18,393 

 

   
 

 

PROPHASE LABS, INC

CONSOLIDATED STATEMENT OF CASH FLOWS

(UNAUDITED)

(in thousands)

 

  For the years ended 
   DECEMBER 31, 2022   DECEMBER 31, 2021 
Cash flows from operating activities          
Net income  $18,463   $6,273 
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Realized loss on marketable debt securities   354    165 
Depreciation and amortization   4,718    3,234 
Amortization of debt discount   4    5 
Amortization on right-of-use assets   343    329 
Loss on sales of assets   (127)   — 
Impairment of secured promissory note receivable   —    3,750 
Stock-based compensation expense   3,986    3,183 
Change in fair value of investment securities   (174)   240 
Non-cash interest income on secured promissory note receivable   —    (316)
Accounts receivable allowances   (761)   3,866 
Inventory valuation reserve   (78)   267 
Bad debt expense, direct write-offs   6,163    — 
Changes in operating assets and liabilities:          
Accounts receivable   (4,498)   (38,197)
Inventory   702    (1,746)
Prepaid and other assets   (617)   1,445 
Other assets   (555)   (368)
Accounts payable and accrued expenses   (1,121)   2,450 
Accrued diagnostic services   (881)   1,890 
Accrued advertising and other allowances   (5)   — 
Deferred revenue   619    2,608 
Deferred tax liability   (138)   — 
Lease liabilities   (301)   130 
Income taxes payable   2,878    — 
Other liabilities   (423)   (2,827)
Net cash provided by (used in) operating activities   28,551    (13,619)
           
Cash flows from investing activities          
Business acquisitions, net of cash acquired   —    (9,066)
Issuance of secured promissory note receivable   —    (1,000)
Purchase of marketable securities   (6,777)   (21,527)
Proceeds from maturities of marketable securities   7,120    — 
Proceeds from sale of marketable debt securities   1,047    15,858 
Proceeds from promissory note   —    300 
Proceeds form dispositions of property and other assets, net   452    — 
Capital expenditures   (3,919)   (4,231)
Net cash (used in) provided by investing activities   (2,077)   (19,666)
           
Cash flows from financing activities          
Proceeds from issuance of common stock from public offering, net   —    35,135 
Proceeds from issuance of common stock and warrants from private offering   —    5,500 
Repayment of common stock for payment of statutory taxes on cashless exercise of stock options   (7,474)   — 
Repayment of note payable   (7,044)   (45)
Repurchases of common shares   (2,152)   (917)
Payment of dividends   (9,353)   (4,546)
Net cash (used in) provided by financing activities   (26,023)   35,127 
           
Increase in cash, cash equivalents and restricted cash   451    1,842 
Cash, cash equivalents and restricted cash, at the beginning of the year   8,658    6,816 
Cash, cash equivalents and restricted cash, at the end of the year  $9,109   $8,658 
           
Supplemental disclosures:          
Cash paid for income taxes  $1,696   $— 
Interest payment on the promissory notes  $763   $1,000 
           
Supplemental disclosure of non-cash investing and financing activities:          
Issuance of common shares related to business acquisition  $—   $3,608 
Issuance of common shares for debt conversion  $600   $— 
Net unrealized loss, investments in marketable debt securities  $1,294   $(164)
Recognize additional goodwill related to deferred tax liability  $—   $362 

 

   
 

 

Non-GAAP Financial Measure and Reconciliation

(unaudited)

 

In an effort to provide investors with additional information regarding our results of operations as determined by accounting principles generally accepted in the United States of America (“GAAP”), we disclose certain non-GAAP financial measures. The primary non-GAAP financial measures we disclose are EBITDA and Adjusted EBITDA.

 

We define EBITDA as net income (loss) before net interest expense, income taxes, depreciation and amortization. Adjusted EBITDA further adjusts EBITDA by excluding acquisition costs, other non-cash items, and other unusual or non-recurring charges (as described in the table below).

 

Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. These non-GAAP financial measures do not reflect a comprehensive system of accounting, differ from GAAP measures with the same names and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. We compute non-GAAP financial measures using the same consistent method from quarter to quarter and year to year. We may consider whether other significant items that arise in the future should be excluded from the non-GAAP financial measures.

 

We use EBITDA and Adjusted EBITDA internally to evaluate and manage the Company’s operations because we believe they provide useful supplemental information regarding the Company’s ongoing economic performance. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our operating results primarily because they exclude amounts that are not considered part of ongoing operating results when planning and forecasting and when assessing the performance of the organization. In addition, we believe that non-GAAP financial information is used by analysts and others in the investment community to analyze our historical results and in providing estimates of future performance and that failure to report these non-GAAP measures could result in confusion among analysts and others and create a misplaced perception that our results have underperformed or exceeded expectations.

 

The following table sets forth the reconciliations of EBITDA and Adjusted EBITDA excluding other costs to the most comparable GAAP financial measures (in thousands):

 

PROPHASE LABS, INC

CONSOLIDATED NON-GAAP FINANCIAL MEASURES

(UNAUDITED)

(in thousands)

   For the years ended 
   DECEMBER 31, 2022   DECEMBER 31, 2021 
GAAP net income (loss) (1) 

$

18,463   $6,273 
Interest, net  611   506 
Income tax expense   4,445    (968)
Depreciation and amortization   4,718    3,233 
EBITDA   28,237    9,044 
Acquisition costs (2)   -    674 
Share-based compensation expense   3,986    3,183 
Non-cash rent expense (3)   236    459 
Bad debt expense   6,163    3,750 
Adjusted EBITDA  $38,622   $17,110 

 

(1)We believe that net income is the financial measure calculated and presented in accordance with GAAP that is most directly comparable to EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA measure the Company’s operating performance without regard to certain expenses. EBITDA and Adjusted EBITDA are not presentations made in accordance with GAAP and the Company’s computation of EBITDA and Adjusted EBITDA may vary from others in the industry. EBITDA and Adjusted EBITDA have important limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of the Company’s results as reported under GAAP.

 

(2)Transaction cost related to the Nebula acquisition.

 

(3)The non-cash portion of rent, which reflects the extent to which our GAAP rent expense recognized exceeds (or is less than) our cash rent payments. For newer leases, our rent expense recognized typically exceeds our cash rent payments, while for more mature leases, rent expense recognized is typically less than our cash rent payments.

 

   

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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prph-20230328.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 prph-20230328_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 prph-20230328_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Mar. 28, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 28, 2023
Entity File Number 000-21617
Entity Registrant Name PROPHASE LABS, INC.
Entity Central Index Key 0000868278
Entity Tax Identification Number 23-2577138
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 711 Stewart Avenue
Entity Address, Address Line Two Suite 200
Entity Address, Address Line Three G
Entity Address, City or Town arden City
Entity Address, State or Province NY
Entity Address, Postal Zip Code 11530
City Area Code (215)
Local Phone Number 345-0919
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0005
Trading Symbol PRPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000868278 2023-03-28 2023-03-28 iso4217:USD shares iso4217:USD shares 0000868278 false 8-K 2023-03-28 PROPHASE LABS, INC. DE 000-21617 23-2577138 711 Stewart Avenue Suite 200 G arden City NY 11530 (215) 345-0919 false false false false Common Stock, par value $0.0005 PRPH NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://prophaselabs.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm prph-20230328.xsd prph-20230328_lab.xml prph-20230328_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "prph-20230328_lab.xml" ] }, "presentationLink": { "local": [ "prph-20230328_pre.xml" ] }, "schema": { "local": [ "prph-20230328.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PRPH", "nsuri": "http://prophaselabs.com/20230328", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-03-28to2023-03-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://prophaselabs.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-03-28to2023-03-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-009202-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-009202-xbrl.zip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end